3-iodo-1,5-dimethyl-1H-pyrazole | 1354706-38-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-iodo-1,5-dimethyl-1H-pyrazole
• 英文别名: 3-iodo-1,5-dimethylpyrazole
• CAS: 1354706-38-9
• 化学式: C₅H₇IN₂
• mdl: MFCD22369796
• 分子量: 222.028
• InChiKey: HTGYBABURKWGBS-UHFFFAOYSA-N

物化性质

• 沸点：
  237.8±20.0 °C(Predicted)
• 密度：
  1.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-iodo-1,5-dimethyl-1H-pyrazole 在 copper(l) iodide 、 2-氯-1,3-二甲基氯化咪唑啉 、 N,N-二异丙基乙胺 、 sodium hydroxide 、 sodium t-butanolate 、 N,N'-二甲基乙二胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 20.0~100.0 ℃ 、26.66 kPa 条件下， 反应 24.0h， 生成 N,N-二环丙基-4-[(1,5-二甲基-1H-吡唑-3-基)氨基]-6-乙基-1,6-二氢-1-甲基-咪唑并[4,5-d]吡咯并[2,3-b]吡啶-7-甲酰胺
  参考文献：
  名称：

  Ni-Catalyzed C–H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543

  摘要：

  BMS-911543 is a complex pyrrolopyridine investigated as a potential treatment for myeloproliferative disorders. The development of a short and efficient synthesis of this molecule is described. During the course of our studies, a Ni-mediated C-N bond formation was invented, which enabled the rapid construction of the highly substituted 2-aminopyridine core. The synthesis of this complex, nitrogen-rich heterocycle was accomplished in only eight steps starting from readily available materials.

  DOI：

  10.1021/acs.joc.5b00572
• 作为产物：
  描述：

  3-氨基-1,5-二甲基吡唑 在 二碘甲烷 、 异戊腈 作用下， 以 异丙醇 为溶剂， 反应 16.0h， 以37.55%的产率得到3-iodo-1,5-dimethyl-1H-pyrazole
  参考文献：
  名称：

  [EN] TYK2 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。

  公开号：

  WO2018075937A1
• 作为试剂：
  描述：

  ethyl 4-amino-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylate 、 3-iodo-1,5-dimethyl-1H-pyrazole 在 3-iodo-1,5-dimethyl-1H-pyrazole 作用下， 以81的产率得到ethyl 4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylate
  参考文献：
  名称：

  J. Org. Chem. 2015, 80, 6001-6011

  摘要：

  DOI：

文献信息

• [EN] FACTOR IXa INHIBITORS<br/>[FR] INHIBITEURS DE FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099694A1

  公开（公告）日：2014-06-26

  The present invention provides a compound of Formula (I) wherein A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more of said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了一种化合物，其化学式为（I），其中A是一个杂环环系统，B是一个杂环环系统或芳香环系统，以及包含一种或多种所述化合物的药物组合物，以及使用所述化合物用于治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• Substituted pyrrolidines as SYK inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US09376441B2

  公开（公告）日：2016-06-28

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，用于治疗各种疾病状态，包括癌症和炎症疾病。在特定实施例中，化合物的结构由公式I给出：其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。
• Effects of Multiple Catalyst Deactivation Pathways and Continuous Ligand Recycling on the Kinetics of Pd-Catalyzed C–N Coupling Reactions
  作者：Neil A. Strotman、Maxime C. Soumeillant、Keming Zhu、Chester E. Markwalter、Carolyn S. Wei、Yi Hsiao、Martin D. Eastgate

  DOI：10.1021/acs.joc.8b02214

  日期：2019.4.19

  Unusual Pd deactivation and inhibition pathways were observed in a C-N coupling system. Irreversible catalyst deactivation involved C-H insertion of Pd into BippyPhos leading to an off-cycle palladaphosphacyclobutene. Product inhibition led to deactivated Pd but released ligand in the process, allowing it to react with additional Pd precursor to re-enter the catalytic cycle. In situ recycling of the ligand allowed for an input L/Pd ratio of << 1 with no impact on reaction kinetics.